Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence

Simple item page
dc.contributor.authorAssaf-Casals, Aia
dc.contributor.authorDbaibo, Ghassan S.
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:10:35Z
dc.date.available2025-01-24T12:10:35Z
dc.date.issued2016
dc.description.abstractABSTRACT: Introduction: Meningococcal disease is a major cause of morbidity and mortality worldwide with reported epidemics and outbreaks in different parts of the world. Despite the availability of antimicrobial therapy, challenges remain in early recognition and prevention of disease. Several vaccines have been developed to date aiming at preventing disease spread. Discussion: MenACWY-TT (Nimenrix™) has been extensively studied for use in different age groups. Phase II and III randomized trials have demonstrated its immunogenicity when administered in children aged 1 year and older, adolescents and adults. It has an acceptable safety profile with minor adverse events comparable to other vaccines. Follow up studies have shown persistence of protective antibodies up to three years. MenACWY-TT was safely and effectively co-administered with different recommended vaccines. Conclusion: MenACWY-TT is a safe and immunogenic vaccine that can be used to protect against these four serogroups in individuals older than 1 year of age. © 2016 Taylor & Francis.
dc.identifier.doihttps://doi.org/10.1080/21645515.2016.1143157
dc.identifier.eid2-s2.0-84961390327
dc.identifier.pmid26900984
dc.identifier.urihttp://hdl.handle.net/10938/32350
dc.language.isoen
dc.publisherTaylor and Francis Inc.
dc.relation.ispartofHuman Vaccines and Immunotherapeutics
dc.sourceScopus
dc.subjectConjugate vaccine
dc.subjectImmunogenicity
dc.subjectMenacwy-tt
dc.subjectMeningococcal disease
dc.subjectNimenrix
dc.subjectRandomized trials
dc.subjectAntibodies, bacterial
dc.subjectClinical trials, phase ii as topic
dc.subjectClinical trials, phase iii as topic
dc.subjectFollow-up studies
dc.subjectHumans
dc.subjectImmunization schedule
dc.subjectMeningococcal infections
dc.subjectMeningococcal vaccines
dc.subjectRandomized controlled trials as topic
dc.subjectVaccines, conjugate
dc.subjectDiphtheria pertussis poliomyelitis tetanus haemophilus influenzae type b hepatitis b vaccine
dc.subjectDiphtheria pertussis tetanus vaccine
dc.subjectHaemophilus influenzae type b vaccine
dc.subjectMeningococcus vaccine
dc.subjectOuter membrane protein
dc.subjectPneumococcus vaccine
dc.subjectTetanus toxoid
dc.subjectBacterium antibody
dc.subjectTetravalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine
dc.subjectVaccine
dc.subjectAge distribution
dc.subjectAntibody titer
dc.subjectAntimicrobial therapy
dc.subjectDrowsiness
dc.subjectDrug safety
dc.subjectFatigue
dc.subjectGastrointestinal symptom
dc.subjectHeadache
dc.subjectHuman
dc.subjectImmune system
dc.subjectInjection site erythema
dc.subjectIrritability
dc.subjectMeningococcosis
dc.subjectMorbidity
dc.subjectMortality
dc.subjectNeisseria meningitidis
dc.subjectNonhuman
dc.subjectPain
dc.subjectPhase 3 clinical trial (topic)
dc.subjectRandomized controlled trial (topic)
dc.subjectReview
dc.subjectSerotype
dc.subjectSwelling
dc.subjectT lymphocyte
dc.subjectUrticaria
dc.subjectVaccination
dc.subjectBlood
dc.subjectFollow up
dc.subjectImmunization
dc.subjectImmunology
dc.subjectPhase 2 clinical trial (topic)
dc.titleMeningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2016-9475.pdf
Size:
479.47 KB
Format:
Adobe Portable Document Format
Download

Collections

Pediatrics and Adolescent Medicine